SAN FRANCISCO, May 26, 2022 (Globe NEWSWIRE) — UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology corporation developing therapeutics to sluggish, halt, or reverse disorders of growing old, today introduced that Michael Samar, existing main economic officer at Assembly Bio, has been appointed to the Company’s board of administrators as its chair of the audit committee and a member of its compensation committee.
“We’re thrilled to add Michael to UNITY’s board of directors. With his powerful qualifications in biotech finance and operations, blended with an energetic new point of view and observe file of execution, Michael’s strategic standpoint will be very important as we focus on executing on our UBX1325 research in DME and AMD and providing critical readouts this yr,” claimed Anirvan Ghosh, Ph.D., chief govt officer of UNITY Biotechnology.
Mr. Samar at this time serves as chief financial officer of Assembly Bio, possessing been promoted from SVP of finance and enterprise functions. His prior working experience contains serving as Vice President of Finance and Internet site Head for the South San Francisco facility at Acorda Therapeutics Director of Money Setting up and Assessment at Onyx Prescription drugs Senior Finance Director, International Planning and Investigation at Agennix, and more and more senior roles in just finance at Johnson & Johnson Pharmaceutical R&D. Mr. Samar received his MBA from Villanova College and his BS in finance from Bryant University. He also serves as Treasurer on the Board of OUTbio Bay Space, Inc., a non-revenue group for LGBTQ+ pros in the biotech and relevant industries.
Concurrent with Mr. Samar’s appointment, Graham K. Cooper has stepped down from the board of directors.
“Graham has been with UNITY by critical areas of its evolution and has contributed enormously to the Business, specially as Chair of Audit Committee. On behalf of the entire UNITY workforce, I would like to thank him for his dedicated support and significant contributions,” explained Keith Leonard, chairman of the board of UNITY Biotechnology. “As we head into the key 2nd 50 % of 2022, we search forward to working intently with Michael and are delighted to welcome him to our board.”
UNITY is creating a new course of therapeutics to sluggish, halt, or reverse disorders of getting old. UNITY’s recent target is on producing medicines to selectively remove or modulate senescent cells and thereby present transformative profit in age-related ophthalmologic and neurologic diseases. Much more details is obtainable at www.unitybiotechnology.com or comply with us on Twitter and LinkedIn.
This press release incorporates ahead-searching statements including statements associated to UNITY’s knowledge of mobile senescence and the purpose it plays in illnesses of growing older, the opportunity for UNITY to build therapeutics to gradual, halt, or reverse illnesses of getting old, together with for ophthalmologic and neurologic conditions, the likely for UNITY to efficiently begin and finish scientific reports of UBX1325 for DME, AMD, and other ophthalmologic conditions, the envisioned timing of enrollment and final results of the medical trials in UBX1325, and UNITY’s expectations concerning the sufficiency of its funds runway. These statements include considerable recognised and unfamiliar threats, uncertainties, and other variables that may perhaps induce our real final results, degrees of exercise, efficiency, or achievements to be materially diverse from the details expressed or implied by these ahead-seeking statements, like the chance that the COVID-19 worldwide pandemic might proceed to negatively effect the improvement of preclinical and scientific drug candidates, together with delaying or disrupting the enrollment of people in medical trials, risks relating to the uncertainties inherent in the drug improvement approach, and challenges relating to UNITY’s understanding of senescence biology. We may possibly not truly achieve the ideas, intentions, or expectations disclosed in our forward-on the lookout statements, and you need to not area undue reliance on our ahead-hunting statements. Genuine effects or gatherings could vary materially from the strategies, intentions and anticipations disclosed in the ahead-on the lookout statements we make. The forward-on the lookout statements in this press launch signify our views as of the day of this release. We foresee that subsequent events and developments will trigger our sights to transform. Having said that, even though we could elect to update these ahead-looking statements at some place in the potential, we have no present intention of accomplishing so except to the extent demanded by applicable law. You really should, hence, not depend on these forward-searching statements as representing our sights as of any day subsequent to the date of this launch. For a even more description of the pitfalls and uncertainties that could bring about precise results to vary from those people expressed in these forward-looking statements, as effectively as hazards relating to the organization of UNITY in basic, see UNITY’s most latest Quarterly Report on Type 10-Q for the quarter ended March 31, 2022, submitted with the Securities and Exchange Commission on May 10, 2022, as perfectly as other documents that may well be filed by UNITY from time to time with the Securities and Trade Fee.
Media Make contact with:
Trader Get hold of: